Unknown

Dataset Information

0

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin.

ABSTRACT:

SUBMITTER: Lamba JK 

PROVIDER: S-EPMC8561291 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin.

Lamba Jatinder K JK   Meshinchi Soheil S  

Haematologica 20211101 11

Similar Datasets

Unknown Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
| S-EPMC3602123 | biostudies-literature
Unknown Relationship between CD33 expression, splicing polymorphism, and <i>in vitro</i> cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330.
| S-EPMC6355486 | biostudies-literature
Unknown CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
| S-EPMC5549451 | biostudies-literature
Unknown Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
| S-EPMC6331698 | biostudies-literature
Unknown No Evidence that <i>CD33</i> rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
| S-EPMC9427256 | biostudies-literature
Unknown Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia.
| S-EPMC7790788 | biostudies-literature
Unknown P473: CRISPR/CAS9 GENE EDITING CLARIFIES THE ROLE OF CD33 SNP RS12459419 IN GEMTUZUMAB OZOGAMICIN-MEDIATED CYTOTOXICITY
| S-EPMC10429479 | biostudies-literature
Unknown Negative Impact of Gemtuzumab Ozogamicin on CD33-Positive Early T-Cell Precursor Acute Lymphoblastic Leukemia: A Case Report.
| S-EPMC10869147 | biostudies-literature
Unknown Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
| S-EPMC7460695 | biostudies-literature
Unknown Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin.
| S-EPMC10155714 | biostudies-literature